secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001437749-24-006538
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports positive preclinical imaging data for MNPR-101-Lu in pancreatic cancer model
--------------------------------------------------------------------------------

- SPECT imaging shows high specificity and durable uptake of MNPR-101-Lu in tumor relative to normal tissue in human pancreatic cancer xenograft model.
- Data help explain near complete tumor elimination observed after single injection of therapeutic radioisotopes bound to MNPR-101 in prior studies.
- MNPR-101-Lu uses Lutetium-177, same therapeutic radioisotope as commercially successful Pluvicto and Lutathera.
- Phase 1 dosimetry trial for diagnostic counterpart MNPR-101-Zr recently cleared by HREC in Australia for advanced cancer patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924006538/0001437749-24-006538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924006538/mnpr20240304_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-006538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer